WO2025008772 - IMPROVED MANUFACTURING PROCESS AND INTERMEDIATES FOR A PYRROLO[2,3-D]PYRIMIDINE COMPOUND AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/008772
Publication Date
09.01.2025
International Application No.
PCT/IB2024/056518
International Filing Date
03.07.2024
Title **
[English]
IMPROVED MANUFACTURING PROCESS AND INTERMEDIATES FOR A PYRROLO[2,3-D]PYRIMIDINE COMPOUND AND USE THEREOF
[French]
PROCÉDÉ DE FABRICATION AMÉLIORÉ ET INTERMÉDIAIRES POUR UN COMPOSÉ PYRROLO[2,3-D]PYRIMIDINE ET LEUR UTILISATION
Applicants **
PFIZER IRELAND PHARMACEUTICALS
Operations Support Group
Ringaskiddy
Cork, IE
Inventors
CUSACK, Declan Thomas Patrick
c/o Pfizer Manufacturing Ireland Unlimited Company
Operations Support Group
Ringaskiddy
Co Cork, IE
DEFOREST, Jacob Cole
c/o Pfizer Inc.
10777 Science Center Drive
San Diego, California 92121, US
DUBBAKA, Srinivas Reddy
c/o Pfizer Asia Manufacturing Pte. Ltd.
Operations Support Group
80 Pasir Panjang Road
Mapletree Business City #21-84, 117372, SG
O'NEILL, Padraig Mary
c/o Pfizer Manufacturing Ireland Unlimited Company
Operations Support Group
Ringaskiddy
Co Cork, IE
Priority Data
63/512,136
06.07.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1472 | |
| EPO | Filing, Examination | 7058 | |
| Japan | Filing | 594 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 4110 |
Total: 13809 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to an improved manufacturing process and intermediates for preparing N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1- sulfonamide.[French]
La présente invention concerne un procédé de fabrication amélioré et des intermédiaires pour préparer du N-((1S,3S)-3-(méthyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide.